



**OBESITY TREATMENT AGENTS PRIOR AUTHORIZATION FORM** (form effective 1/6/2025)

Prior authorization guidelines for **Obesity Treatment Agents** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <https://www.pa.gov/en/agencies/dhs/resources/for-providers/ma-for-providers/pharmacy-services>.

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		# of pages: _____	Prescriber name:	
Name of office contact:			Specialty:	
Contact's phone number:			NPI:	State license #:
LTC facility contact/phone:			Street address:	
Beneficiary name:			City/state/zip:	
Beneficiary ID#:	DOB:	Phone:	Fax:	

**CLINICAL INFORMATION**

Drug requested:	
Strength & package size/quantity/refills:	
Additional strengths / quantity for each / refills for each to allow for <u>dose titration</u> :	
Directions:	
Diagnosis ( <i>submit documentation</i> ):	Dx code ( <i>required</i> ):
Does the beneficiary have any contraindications to the requested medication?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>
<b>ATTESTATION from the prescriber:</b> Was beneficiary recently counseled about lifestyle changes and behavior modifications such as a healthy diet and increased physical activity?	<input type="checkbox"/> Yes <input type="checkbox"/> No



Complete all sections that apply to the beneficiary and this request.

*Check all that apply and submit documentation for each item.*

**INITIAL requests**

**1. The beneficiary is 18 years of age or older and:**

Pre-treatment weight: \_\_\_\_\_ Pre-treatment BMI: \_\_\_\_\_

- Has a BMI greater than or equal to 30 kg/m<sup>2</sup>
- Has a BMI greater than or equal 27 kg/m<sup>2</sup> and less than 30 kg/m<sup>2</sup> AND at least one of the following weight-related comorbidities:

- |   |  |
|---|--|
| <input type="checkbox"/> cardiovascular disease | <input type="checkbox"/> obstructive sleep apnea |
| <input type="checkbox"/> dyslipidemia           | <input type="checkbox"/> prediabetes             |
| <input type="checkbox"/> hypertension           | <input type="checkbox"/> type 2 diabetes         |
| <input type="checkbox"/> metabolic syndrome     | <input type="checkbox"/> other (list): _____     |

- Is a candidate for treatment based on degree of adiposity, waist circumference, history of bariatric surgery, BMI exceptions for beneficiary's ethnicity, etc. AND has at least one of the following weight-related comorbidities:

- |   |  |
|---|--|
| <input type="checkbox"/> cardiovascular disease | <input type="checkbox"/> obstructive sleep apnea |
| <input type="checkbox"/> dyslipidemia           | <input type="checkbox"/> prediabetes             |
| <input type="checkbox"/> hypertension           | <input type="checkbox"/> type 2 diabetes         |
| <input type="checkbox"/> metabolic syndrome     | <input type="checkbox"/> other (list): _____     |

**2. The beneficiary is less than 18 years of age and:**

Pre-treatment BMI: \_\_\_\_\_ Pre-treatment BMI z-score: \_\_\_\_\_

- Has a BMI in the 95<sup>th</sup> percentile or greater standardized for age and sex based on current CDC charts

**3. Request is for EVEKEO (amphetamine) ODT/tablet:**

- Was assessed for potential risk of misuse, abuse, and/or addiction based on family and social history
- Was educated regarding the potential adverse effects of stimulants, including the risk of misuse, abuse, and addiction
- Has a history of trial and failure of or a contraindication or an intolerance to all other Obesity Treatment Agents (preferred and non-preferred)
- Has prescriber documentation explaining why Evekeo (amphetamine) is needed and a plan for tapering
- For a beneficiary with a history of substance dependency, abuse, or diversion:
  - Has results of a recent UDS for licit and illicit drugs with the potential for abuse (including specific testing for oxycodone, fentanyl, and tramadol) that is consistent with prescribed controlled substances

**4. Request is for a PREFERRED Obesity Treatment Agent containing a GLP-1 RECEPTOR AGONIST (eg, Saxenda, Wegovy, Zepbound) (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.):**

- Has a concurrent diagnosis of diabetes mellitus OR has taken an antidiabetic drug in the last 120 days AND:
  - Has a history of trial and failure of or a contraindication or an intolerance to the preferred Hypoglycemics, Incretin Mimetics/Enhancers containing a GLP-1 receptor agonist:
    - Ozempic
    - Trulicity
    - Victoza
- Does NOT have diabetes mellitus and has NOT taken an antidiabetic drug in the past 120 days



5. Request is for a **NON-PREFERRED Obesity Treatment Agent containing a GLP-1 RECEPTOR AGONIST** (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.):
- Has a history of trial and failure of or a contraindication or an intolerance to the preferred Obesity Treatment Agents containing a GLP-1 receptor agonist that are medically accepted for the beneficiary's diagnosis:
    - Saxenda
    - Wegovy
    - Zepbound
  - Has a history of trial and failure of or a contraindication or an intolerance to the preferred Hypoglycemics, Incretin Mimetics/Enhancers containing a GLP-1 receptor agonist that are medically accepted for the beneficiary's diagnosis:
    - Ozempic
    - Trulicity
    - Victoza
6. Request is for **ANY OTHER NON-PREFERRED Obesity Treatment Agent** (ie, NOT Evekeo [amphetamine] or a drug containing a GLP-1 receptor agonist) (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.):
- Has a history of trial and failure of or a contraindication or an intolerance to the preferred Obesity Treatment Agents approved or medically accepted for the beneficiary's diagnosis or indication:
 

<input type="checkbox"/> phentermine capsule or tablet	<input type="checkbox"/> Wegovy
<input type="checkbox"/> Saxenda	<input type="checkbox"/> Zepbound

**RENEWAL requests**

1. For a beneficiary is **18 years of age or older**:
- Pre-treatment weight: \_\_\_\_\_ Current weight: \_\_\_\_\_
2. For a beneficiary is **less than 18 years of age**:
- Pre-treatment BMI: \_\_\_\_\_ Current BMI: \_\_\_\_\_
- Pre-treatment BMI z-score: \_\_\_\_\_ Current BMI z-score: \_\_\_\_\_
3. **All requests:**
- The dose of the requested medication is currently being titrated
  - The beneficiary experienced a percent reduction in body weight (for beneficiaries 18 years of age or older) or BMI or BMI z-score (for beneficiaries less than 18 years of age) that is consistent with the recommended cutoff in the FDA-approved package labeling, peer-reviewed medical literature, or consensus treatment guidelines after 3 months of therapy with the maximum recommended/tolerated dose
  - The beneficiary experienced an improvement in degree of adiposity or waist circumference from baseline
  - The beneficiary experienced clinical benefit with the requested medication in at least one weight-related comorbidity from baseline, such as dyslipidemia, hypertension, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, metabolic syndrome, etc.
4. Request is for **Evekeo (amphetamine) ODT/tablet**:
- Has prescriber documentation explaining why Evekeo (amphetamine) is needed and a plan for tapering (submit documentation)
  - For a beneficiary with **a history of substance dependency, abuse, or diversion**:
    - Has results of a recent UDS for licit & illicit drugs with the potential for abuse (including specific testing for oxycodone, fentanyl, and tramadol) that is consistent with prescribed controlled substances
5. Request is for a **NON-PREFERRED Obesity Treatment Agent containing a GLP-1 RECEPTOR AGONIST** (Refer to



<https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.):

Has a history of trial and failure of or a contraindication or an intolerance to the preferred Obesity Treatment Agents containing a GLP-1 receptor agonist that are medically accepted for the beneficiary's diagnosis:

- Saxenda
- Wegovy
- Zepbound

Has a history of trial and failure of or a contraindication or an intolerance to the preferred Hypoglycemics, Incretin Mimetics/Enhancers containing a GLP-1 receptor agonist that are medically accepted for the beneficiary's diagnosis:

- Ozempic
- Trulicity
- Victoza

6. Request is for **ANY OTHER NON-PREFERRED Obesity Treatment Agent** (ie, NOT Evekeo [amphetamine] or a drug containing a **GLP-1 receptor agonist**) (Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in this class.):

Has a history of trial and failure of or a contraindication or an intolerance to the preferred Obesity Treatment Agents approved or medically accepted for the beneficiary's diagnosis or indication:

- phentermine capsule or tablet
- Wegovy
- Saxenda
- Zepbound

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

Prescriber Signature:

Date:

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.